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Abstract
Background: Numerous studies have shown that long non-coding RNAs (lncRNAs) behave as a novel class of
transcript during multiple cancer processes, such as cell proliferation, apoptosis, migration, and invasion. LINC00152
is located on chromosome 2p11.2, and has a transcript length of 828 nucleotides. The biological role of LINC00152
in LAD(lung adenocarcinoma) remains unknown.
Methods: Quantitative reverse transcription PCR(qRT-PCR) was used to detect LINC00152 expression in 60
human LAD tissues and paired normal tissues. In vitro and in vivo studies showed the biological function of
LINC00152 in tumour progression. RNA transcriptome sequencing technology was performed to identify the
downstream suppressor IL24(interleukin 24) which was further examined by qRT-PCR, western bolt and rescue
experiments. RNA immunoprecipitation (RIP), RNA pulldown, and Chromatin immunoprecipitation (ChIP)
assays were carried out to reveal the interaction between LINC00152, EZH2 and IL24.
Results: LINC00152 expression was upregulated in 60 human LAD tissues and paired normal tissues. High
levels of LINC00152 expression were correlated with advanced TNM stage, larger tumor size, and lymph
node metastasis, as well as shorter survival time. Silencing of LINC00152 suppressed cell growth and induced
cell apoptosis. LINC00152 knockdown altered the expression of many downstream genes, including IL24.
LINC00152 could interact with EZH2 and inhibit IL24 transcription. Moreover, the ectopic expression of IL24
repressed cell proliferation and partly reversed LINC00152 overexpression-induced promotion of cell growth
in LAD.
Conclusions: Our study reveals an oncogenic role for LINC00152 in LAD tumorigenesis, suggesting that it
could be used as a therapeutic target in LAD treatment.
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Background
Non-small cell lung cancer (NSCLC) accounts for 80% of
all lung cancer cases [1]. The incidence of NSCLC has
increased annually, and it is becoming one of the leading
causes of death from cancer worldwide. Lung adenocar-
cinoma (LAD) is the most common histological type of
NSCLC, and because of its tendency to form haema-
togenous metastasis, patients often die of relapse and
metastasis [2]. Although advanced detection measures
and treatments including surgery, chemotherapy, radio-
therapy, and targeted therapy are widely used, the likeli-
hood of a complete cure is slim [3, 4]. Therefore, a
thorough understanding of the molecular mechanisms
involved in the development and progression of LAD
could provide more effective diagnostic markers and tar-
gets for LAD patient therapy [5].
The completion of the human genome and GENCODE
projects revealed that less than 3% of the human genome
codes for proteins, while at least 75% is transcribed into
non-coding RNAs, including microRNAs (miRNAs)
(<200 nt) and long non-coding RNAs (lncRNAs) (>200 nt).
Many studies have shown that miRNAs can act either
as tumor suppressors or oncogenes in various cancers
through regulating target gene expression by binding 3′
untranslated regions and repressing transcription [6, 7].
Recently, lncRNAs have drawn attention as potential
biological regulators involved in a wide range of cellular
activities such as cell proliferation, apoptosis, migra-
tion, and invasion [8]. The underlying mechanisms of
lncRNAs are varied, and include acting as competitive
endogenous RNAs similar to miRNA sponges, chroma-
tin remodelling, and histone protein modification [9].
Moreover, the dysregulation of lncRNAs has been
linked with human diseases including cancers [10]. For
example, the SP-1-induced overexpression of tissue
differentiation-inducing non-protein coding RNA was
previously shown to promote cell proliferation by influ-
encing KLF2 mRNA stability in gastric cancer [11]. Nie
et al. also reported that UCA1 competitively sponged
miR193a-3p and induced expression of the miR-193a-
3p target gene ERBB4 in NSCLC [12]. Additionally, in
an earlier study, we found that the long non-coding
RNA PVT1 suppressed cell growth and induced apop-
tosis by binding to the enhancer of zeste homolog 2
(EZH2) protein, a histone methyltransferase of the
PRC2 complex, in LAD [13].
Long intergenic non-coding RNA 00152 (LINC00152)
is located on chromosome 2p11.2, and has a transcript
length of 828 nucleotides. It was first reported to be
highly expressed in gastric tissues and cells [14]. Further
work showed that LINC00152 was involved in cell pro-
liferation, apoptosis, migration, and invasion in gastric
cancer and clear cell renal cell cancer, suggesting that it
could be viewed as a potential target in both cancers
[15–17]. LINC00152 was also observed to act as a novel
biological predictor in hepatocellular carcinoma (HCC),
being positively correlated with advanced TNM stage
and poor overall survival [18]. However, the expression
pattern, functional role, underlying mechanism, and clin-
ical significance of LINC00152 in LAD remain unclear.
In this study, we evaluated the expression level of
LINC00152 in LAD tissues and cells by analyzing gene
profiling data from the TCGA database and validating
these in a cohort of 60 paired tissues. We found that
LINC00152 was significantly up-regulated in LAD tis-
sues compared with normal lung tissues, and that in-
creased LINC00152 levels were associated with poor
prognosis and short survival time of LAD patients.
LINC00152 was also shown to bind to PRC2 protein,
thereby inhibiting the expression of interleukin (IL)24
and promoting LAD cell proliferation.
Methods
Tissue samples and clinical data collection
A total of 60 paired LAD and adjacent non-tumor lung
tissues were obtained from patients who underwent
surgery at The First and Second Affiliated Hospital of
Nanjing Medical University from 2012 to 2013. All pa-
tients were diagnosed with LAD (stages I, II, and III)
according to histopathological evaluation. Clinicopath-
ological characteristics of LAD patients are shown in
Table 1. No chemotherapy or radiotherapy was con-
ducted in these patients prior to surgery. All tissues
were stored at −80°C. All human tissue samples were ob-
tained with written informed consent from all subjects, and
this project was approved by the Research Ethics Commit-
tee of The Second Affiliated Hospital of Nanjing Medical
University. All methods were carried out in accordance
with the guidelines approved by the Research Ethics
Committee of The Second Affiliated Hospital of
Nanjing Medical University. And the study protocol
was approved by the Research Ethics Committee of
The Second Affiliated Hospital of Nanjing Medical
University.
Cell culture
We obtained five LAD cell lines (A549, SPCA1, PC-9,
H1299, and H1975) and the normal human bronchial epi-
thelial cell line 16HBE from the Institute of Biochemistry
and Cell Biology of the Chinese Academy of Sciences
(Shanghai, China). A549, H1975, and H1299 cells were
cultured in RPMI-1640 medium (GIBCO-BRL), and
16HBE, SPC-A1, and PC9 cells were grown in DMEM
medium (GIBCO-BRL). Both media were supplemented
with 10% fetal bovine serum (FBS; Gibco) and antibi-
otics (100 U/ml penicillin and 100 mg/ml strepto-
mycin) (Invitrogen, Carlsbad, CA) were maintained in
a humidified air atmosphere at 37°C with 5% CO2.
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RNA isolation and qRT-PCR
Total RNA was extracted from tissues or cultured cells
using TRIzol reagent (Invitrogen). Total RNA (1 μg) was
reverse transcribed to cDNA in a final volume of 20 μl
using random primers under standard conditions with
the PrimeScript RT Reagent Kit (Takara, Dalian, China).
We performed real-time PCR analyses using SYBR Pre-
mix Ex Taq (Takara) according to the manufacturer’s in-
structions. Results were normalised to the expression of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
and data were collected based on the comparative cycle
threshold (CT) (2−ΔΔCT) method. Specific primer se-
quences are listed in Additional file 1: Table S2.
RNA interference
A549 and SPCA1 cell lines were seeded in six-well
plates, then 24 h later they were transfected with specific
siRNAs and plasmid vectors using Lipofectamine 2000.
We purchased three LINC00152 siRNAs (si-LINC00152
1#, 2#, and 3#), EZH2 siRNA, and scrambled negative
control siRNA (si-NC) from Invitrogen. LINC00152 and
EZH2 siRNA sequences are listed in Additional file 1:
Table S2. Cells were harvested for qRT-PCR or western
blot analysis 48 h after transfection.
Plasmid generation
Full-length LINC00152 cDNA was synthesised by Realgene
(Nanjing, China) and ligated into the pcDNA3.1(+) vector
(Invitrogen). The IL24 sequence was also synthesised and
subcloned into the pCDNA3.1(+) vector (GENECHEM,
Shanghai, China). Plasmid vectors (pcDNA3.1-LINC00152,
pcDNA3.1-IL24, and empty vector) were transfected into
LAD cells cultured in six-well plates using the X-
tremeGENE HP DNA transfection reagent (Roche, Basel,
Switzerland). Cells were harvested for qRT-PCR or western
blot analysis 48 h after transfection.
Cell proliferation assays
Cell viability was measured using the Cell Proliferation
Reagent Kit I (MTT; Roche Applied Science). A549 and
SPCA1 cells transfected with si-LINC00152, and PC-9
cells transfected with pCDNA-LINC00152 were seeded
in 96-well plates. Cell viability was monitored every 24 h
following the manufacturer’s instructions. For the colony
formation assay, a total of 1 × 103 transfected cells were
placed in each well of 6-well plates and maintained in
media containing 10% FBS for 2 weeks, during which
the medium was replaced every 3 days. After 14 days,
the colonies were treated with methanol and stained
with 0.1% crystal violet (Sigma-Aldrich). Visible colonies
were counted. Wells were assessed in triplicate for each
treatment group.
Flow cytometric analysis
A549 and SPCA1 cells transfected with si-LINC00152
were harvested 48 h after transfection by trypsinisation.
After double staining with FITC-Annexin V and propi-
dium iodide (PI) using the FITC Annexin V Apoptosis
Detection Kit (BD Biosciences) according to the manu-
facturer’s recommendations, the cells were analysed by
flow cytometry (FACScan®; BD Biosciences) equipped
with CellQuest software (BD Biosciences). Cells were
classified as viable, dead, early apoptotic, and apoptotic,
then the relative number of early apoptotic cells was
compared with that in cells transfected with control
transfectant. Cells for cell cycle analysis were stained
with PI using the CycleTEST™ Plus DNA Reagent Kit
(BD Biosciences) following the protocol, and analysed by
FACScan. The percentage of cells in G0/G1, S, and G2/
M phase were counted and compared.
Western blot assay and antibodies
Cell protein lysates were separated by 10% sodium dodecyl
sulphate (SDS) polyacrylamide gel electrophoresis, trans-
ferred to 0.22 μm NC membranes (Sigma) and incubated
with specific antibodies. The ECL chromogenic substrate
was quantified by densitometry (Quantity One software;
Bio-Rad). An anti-GAPDH antibody was used as a control,
anti-EZH2, and anti-Bcl-xl antibodies (1:1000) were
Table 1 Relationship between LINC00152 expression and
clinicopathological characteristics of LAD patients





> 65 27 (45%) 12 15
≤ 65 33 (55%) 18 15
Gender 0.598
Male 24 (40%) 13 11
Female 36 (60%) 17 19
TNM stage 0.035*
I + II 24 (40%) 8 16
IIIa 36 (60%) 22 14
Tumor size 0.020*
≤ 5 16 (26.7%) 4 12
> 5 44 (73.3%) 26 18
Lymph node metastasis 0.001*
Negative 22 (36.7%) 5 17
Positive 38 (63.3%) 25 13
Smoking history 0.301
Smokers 28 (46.7%) 16 12
Never smoker 32 (53.3%) 14 18
*P < 0.05
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purchased from Cell Signaling Technology, Inc., and anti-
IL24 antibodies (1:1000) were purchased from Abcam.
Ethynyldeoxyuridine (EdU) analysis
The EdU labelling/detection kit (Ribobio, Guangzhou,
China) was used to assess cell proliferation. Cells were
grown in 96-well plates at 5 × 103 cells/well. Forty-eight
hours after transfection, 50 μM EdU labelling media was
added to cells and they were incubated for 2 h at 37°C
under 5% CO2. After treatment with 4% paraformalde-
hyde and 0.5% Triton X-100, cells were stained with
anti-EdU working solution. DAPI was used to label cell
nuclei. The percentage of EdU-positive cells was
calculated under fluorescent microscopy. Five fields of
view were randomly assessed for each treatment group.
Tumor formation assay in a nude mouse model
Male athymic BALB/c mice (5-weeks-old) were maintained
under specific pathogen-free conditions and manipulated
according to protocols approved by the Shanghai Medical
Experimental Animal Care Commission. A549 cells were
stably transfected with sh-LINC00152 and empty vector
and harvested from 6-well cell culture plates, washed with
phosphate-buffered saline, and re-suspended at a concen-
tration of 1 × 108 cells/ml. A total of 100 μL of suspended
cells was subcutaneously injected into a single side of the
Fig. 1 Relative LINC00152 expression in LAD tissues and its clinical significance. a Bioinformatics tools “lncRNAtor” (http://lncrnator.ewha.ac.kr/
expression.htm) detection of LINC00152 expression in human LAD(n = 46) compared with normal tissues(n = 245). b Relative expression of
LINC00152 in LAD tissues compared with non-cancerous tissues analyzed by TCGA database. c LINC00152 expression in lung adenocarcinoma
(n = 60) compared with normal tissues (n = 60) was examined by qRT-PCR and normalized to GAPDH expression. d LINC00152 expression was
analyzed by qRT-PCR in 6 NSCLC cell lines(5 lung adenocarcinoma cell lines and 1 squamous carcinoma cell line), compared with the normal
bronchial epithelial cell line(HBE). e, f Kaplan-Meier progression-free survival time and overall survival curves according to LINC00152 expression
levels. *P < 0.05, **P < 0.01
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posterior flank of each mouse. tumor growth was examined
every 3 days, and tumor volumes were calculated using the
equation V = 0.5 × D × d2 where V represents volume; D
represents longitudinal diameter; and d represents latitu-
dinal diameter. At 18 days post-injection, mice were eutha-
nised, and the subcutaneous growth of each tumor was
examined. This study was carried out in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Committee on
the Ethics of Animal Experiments of Nanjing Medical
University.
Subcellular fractionation
The separation of nuclear and cytosolic fractions was
performed using the PARIS Kit (Life Technologies,
Carlsbad, CA) following the manufacturer’s instructions.
RNA immunoprecipitation (RIP) assay
RIP was performed using the EZ-Magna RIP kit (Millipore,
Billerica, MA) following the manufacturer’s protocol.
A549 and SPCA1 cells at 80–90% confluency were
scraped off the tissue culture plate, then lysed in
complete RIP lysis buffer. A total of 100 μl of whole
cell extract was incubated with RIP buffer containing
magnetic beads conjugated with antibodies against
EZH2, SUZ12, or LSD1 or control IgG (Millipore) for
6 h at 4°C. The beads were washed with wash buffer,
then the complexes were incubated with 0.1% SDS/0.5
mg/ml Proteinase K (30 min at 55°C) to remove pro-
teins. The RNA concentration was measured using a
NanoDrop spectrophotometer (Thermo Scientific) and
its quality was assessed using a bioanalyser (Agilent, Santa
Clara, CA). Finally, immunoprecipitated RNA was purified
and analysed by qRT-PCR.
Chromatin immunoprecipitation
A549 and SPCA1 cells were treated with formaldehyde and
incubated for 10 min to generate DNA–protein cross-links.
Cell lysates were then sonicated to generate chromatin frag-
ments of 200–300 bp and immunoprecipitated with anti-
bodies specific for EZH2, LSD1, H3K27me3, or H3K4me2
(CST) or IgG as a control. Precipitated chromatin DNA
was recovered and analysed by qRT-PCR.
RNA pulldown assays
The pCDNA3.1-LINC00152 vector was cleaved by restric-
tion enzyme Nru I and treated with RNase-free DNase I
(New England Biolabs). LINC00152 was transcribed from
this vector by mMESSAGE mMACHINE T7® Kit
(Ambion, USA) and purified using the RNeasy Mini Kit
(Qiagen, Valencia, CA) in vitro. The 3′ end of LINC00152
was biotin-labelled according to the instructions of the
Pierce RNA 3′ End Desthiobiotinylation Kit (Thermo
Fig. 2 The effects of LINC00152 on LAD cell proliferation in vitro. a, b MTT assays were performed to detect the viability of si-LINC00152 transfected
A549 and SPCA1 cells or pcDNA-LINC00152 transfected H1299 cells. c, d Colony formation assays and EdU immunostaining assays were conducted to
determine the proliferation of transfected LAD cells. e, f Colonies and EdU positive cells were counted and captured. Values are shown as the mean ± s.d
in three independent experiments. *P < 0.05, **P < 0.01
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Scientific, USA). One mg of protein from SPCA1 cell ex-
tracts was then mixed with 50 pmol of biotinylated RNA,
and incubated with 50 μL of magnetic beads for 1 h at 4°C
(Thermo Scientific). The RNA–protein complex was iso-
lated from magnetic beads using Biotin Elution Buffer and
boiled in SDS buffer for 5 min. The retrieved protein was
detected using standard western blotting techniques.
Immunohistochemical (IHC) analysis
Primary tumors were immunostained for Ki-67 and IL24
as previously described.
Statistical analysis
The Student’s t-test (two-tailed), one-way analysis of
variance, and the Mann–Whitney U test were con-
ducted to analyse in vitro and in vivo data by SPSS
17.0 software. p values less than 0.05 were considered
significant.
Results
LINC00152 is overexpressed in LAD tissues
We first analysed lncRNA expression in LAD tissues
(n = 291) using the bioinformatics tool “lncRNAtor”
(http://lncrnator.ewha.ac.kr/expression.htm), and found
that LINC00152 was highly expressed in LAD tumor
tissues at ~2.63-fold higher levels than it in normal tis-
sues (Fig. 1a). We also evaluated LINC00152 expression
in 30 LAD samples and adjacent normal samples from
the Cancer Genome Atlas database. As shown in Fig. 1b
(P < 0.01), LINC00152 was significantly upregulated in
LAD tissues. Quantitative reverse transcription(qRT-
PCR) showed that LINC00152 expression was increased
Fig. 3 LINC00152 knockdown promoted G1 arrest and inducedd apoptosis in LAD cells. A549 and SPCA1 cells were transfected with scrambled
or si-LINC00152 2#, 3#. a, b Cell cycle was analyzed in A549 and SPCA1 cells. c, d Flow cytometry was performed to determine the apoptptic rates
of cells. Values are shown as the mean ± s.d in three independent experiments. *P < 0.05, **P < 0.01
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in 60 LAD tumor samples compared with paired adja-
cent normal tissues (Fig. 1c). We also assessed its ex-
pression level in 16HBE cells and six human LAD cell
lines using qRT-PCR. A549 and SPCA1 cells expressed
the highest levels of LINC00152, while H1299
expressed lower LINC00152 levels (Fig. 1d). These re-
sults suggested that LINC00152 played an essential bio-
logical role in LAD tumorigenesis and progression.
LINC00152 expression associates with poor prognosis of
LAD patients
To assess the significance of LINC00152 overexpression
in LAD, we evaluated the correlation between LINC00152
expression and patient clinicopathological characteristics.
Sixty LAD patients were classified into two groups ac-
cording to the median ratio (2.18) of relative LINC00152
expression in tumor tissues: high LINC00152 group
(n = 30, LINC00152 expression ratio ≤ median ratio) and
low LINC00152 group (n = 30, LINC00152 expression
ratio ≥ median ratio). As shown in Table 1, higher levels of
LINC00152 were significantly associated with advanced
TNM stage (p = 0.035), larger tumor size (p = 0.020), and
lymph node metastasis (p = 0.001). However, there was no
obvious relationship between LINC00152 expression and
other clinical parameters such as age (p = 0.436), sex
(p = 0.598), or smoking history (p = 0.301) (Table 1).
Kaplan–Meier survival analysis was used to examine the
association between LINC00152 and LAD patient progno-
sis. Notably, patients with higher LINC00152 expression
levels had significantly shorter progression-free survival
time and overall survival time than those expressing lower
levels of LINC00152 (p = 0.012) (Fig. 1e, f ).
LINC00152 silencing inhibits LAD cell proliferation
To investigate the potential role of LINC00152 in LAD
cells, we synthesised three small interfering (si)RNAs
to silence LINC00152 expression, and 48 h post-
transfection observed knockdown of LINC00152 by
88% in A549 cells and 92% in SPCA1 cells compared
with control cells. We also upregulated LINC00152
expression in H1299 cells by 113-fold by transfecting
them with the pcDNA3.1-LINC00152 vector (Additional
file 2: Figure S1a, b).
Because lncRNAs are involved in many biological pro-
cesses, we next examined the contribution of LINC00152
to LAD development. MTT assays showed that A549 and
SPCA1 cell viability was significantly decreased after knock-
down of LINC00152 expression (Fig. 2a). By contrast,
H1299 cells exhibiting increased LINC00152 expression
Fig. 4 Effects on tumor proliferation after LINC00152 knockdown in vivo. a A549 cells transfected with empty vector or sh-LINC00152 were injected into
the nude mice(n = 8). Tumors before and after carrying from the nude mice. b Tumor volume was calculated every 3 days. c Tumor weight was measured
after tumor removal. d qRT-PCR was used to examine the average expression of LINC00152 in tumor tissues formed from A549/empty vector and A549/
sh-LINC00152. e The tumor sections were under H&E staing and IHC staining using antibodies against Ki-67. *P < 0.05, **P < 0.01
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levels showed a higher cell viability rate than controls
(Fig. 2b). Additionally, the colony formation ability of A549
and SPCA1 cells was greatly attenuated following
LINC00152 knockdown (Fig. 2c), while clonogenic survival
was markedly increased in LINC00152-overexpressing
H1299 cells (Fig. 2d). Similar results were observed by
5-ethynyl-2-deoxyuridine EdU(red)/DAPI (blue) immu-
nostaining assays (Fig. 2e, f ). These findings indicated
that LINC00152 behaved as an oncogene promoting
LAD cell proliferation.
Knockdown of LINC00152 induces G1 arrest and cell
apoptosis
To further explore whether the cell cycle progression
alteration contributes to the effect of LINC00152 knock-
down on cell viability, flow cytometric analysis was used
to examine cell cycle progression. A549 and SPCA1 cells
transfected with si-LINC00152 2# or 3# showed an
elevated cell cycle arrest at the G1/G0 phase (Fig. 3a, b).
Flow cytometric analysis also revealed that LINC00152
knockdown by LINC00152 siRNA increased apoptosis in
LAD cells (Fig. 3c, d). Moreover, Bcl-xl protein levels were
significantly decreased in cells transfected with siRNA
(Additional file 2: Figure S1c). These results confirmed
that the LINC00152 downregulation-mediated inhibition
of LAD cell proliferation could be attributed to apoptosis
and cell cycle arrest at the G1/S checkpoint.
LINC00152 promotes the tumorigenesis of LAD cells in vivo
We next constructed a xenograft mouse model to verify
the oncogenic role of LINC00152 in LAD tumorigenesis.
A549 cells stably transfected with sh-LINC00152 or empty
vector (and H1299 cells stably transfected with pcDNA-
LINC00152 or empty vector) were injected into nude mice.
After 18 days, we found that LINC00152 silencing substan-
tially decreased tumor growth, and that the tumors which
Fig. 5 LINC00152 interacted with EZH2, and regulated IL24 expression. a qRT-PCR was performed to detect the relative LINC00152 levels in A549
and SPCA1 cell cytoplasm and nucleus. GAPDH was used as cytoplasm control and U6 was used as nucleus control. b RIP experiments were performed
in A549,SPCA1 cells and the corprecipitated RNA was subjected to qRT-PCR for LINC00152. Expression levels of LINC00152 RNA are as fold enrichment in
EZH2,LSD1,SUZ12 relative to IgG immunoprecipitates. c RNA pulldown and western blotting assays revealed biotinylated LINC00152 could bind to EZH2
and LSD1. d qRT-PCR was used to analyze the mRNA expression levels of tumor suppressor genes in scrambled and si-LINC00152 2#/3# treated LAD cells.
e Western blotting analysis of IL24 protein level in LINC00152knockdown A549 and SPCA1 cells, GAPDH protein was used as an internal control. f IL24
mRNA level in A549 and SPCA1 cells transfected with si-EZH2. g Western blotting were performed to detect the IL24 protein level in A549
and SPCA1 cells. h ChIP-qRT-PCR of EZH2 occupancy and H3K27me3 binding in the IL24 promoter in A549 and SPCA1 cells treated with
si-LINC00152(48h) or scrambled siRNA, IgG was used as a negative control. Values are shown as the mean ± s.d in three independent
experiments. *P < 0.05, **P < 0.01
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formed in the sh-LINC00152 group of mice were smaller
than those in the control group (Fig. 4a, b). Additionally,
the tumor weight of the sh-LINC00152 group was less
than that of the control (Fig. 4c). In contrast, LINC00152
overexpression could promote tumor growth (Additional
file 3: Figure S2a, b). qRT-PCR analysis showed that tumor
tissues from the sh-LINC00152 group exhibited lower
LINC00152 expression than those of the empty vector
group (Fig. 4d). Moreover, immunohistochemical analysis
revealed decreased Ki-67 staining, reflecting a lower prolif-
eration index, in tumor tissues formed from A549 cells
with stable LINC00152 knockdown (Fig. 4e). Collectively,
these results indicated that LINC00152 was involved in
oncogenic activation in LAD in vivo.
LINC00152 directly interacted with EZH2/LSD1 in LAD cells
As shown in Fig. 5a, LINC00152 expression in nucleus
was higher than it in cytosol in A549 and SPCA1 cell
lines, indicating that it may function as a regulator of
transcription levels. Previous studies showed that
lncRNAs influence the expression of downstream targets
via recruiting PRC2 or LSD1 proteins [19, 20]. To deter-
mine whether LINC00152 regulates target genes using a
similar mechanism, we carried out RNA immunoprecipi-
tation (RIP) assays which revealed that LINC00152 bound
directly to EZH2 and LSD1 in both A549 and SPCA1 cells
(Fig. 5b). RNA pulldown assays also confirmed the inter-
action between LINC00152 and EZH2 or LSD1 (Fig. 5c).
Interleukin (IL)24 is the key underlying target of LINC00152
We used RNA transcriptome sequencing to identify genes
that were differentially expressed between LINC00152-de-
pleted SPCA1 cells and control cells. Of 1742 differen-
tially expressed transcripts screened out by database
analysis (fold-change >2, p < 0.05), 763 were upregulated
and 979 were downregulated (Table 2 and Additional file
4: Table S1). We selected nine representative genes veri-
fied as tumor suppressors in A549 and SPCA1 cell lines.
Of these, IL24 showed the highest fold-change of upreg-
ulation in LINC00152-depleted SPCA1 and A549 cells
(Fig. 5d). Additionally, western blot analysis showed that
IL24 protein levels were increased in LAD cells trans-
fected with LINC00152 (Fig. 5e). qRT-PCR and western
blot analysis showed that EZH2 or LSD1 inhibition up-
regulated the mRNA and protein expression of IL24
(Fig. 5f, g + Additional file 2: Figure S1d, e + Additional
file 5: Figure S3a–c).
We next investigated whether LINC00152 silenced
IL24 transcription by recruiting EZH2 or LSD1 to the
IL24 promoter region. We used chromatin immuno-
precipitation (ChIP) to determine the association of
IL24 and EZH2 or LSD1. EZH2 was shown to bind the
promoter region of IL24, while LINC00152 knockdown
reduced the histone H3 lysine 27 trimethylation
(H3K27me3) occupancy of the IL24 promoter locus
(Fig. 5h). However, LSD1 did not bind the IL24
promoter locus (Additional file 5: Figure S3d). These
results indicated that LINC00152 repression of target
IL24 expression occured, at least partially, through
interaction with EZH2.
Ecotopic expression of IL24 inhibited LAD cell proliferation
To investigate the functional role of IL24 in the LAD
cell phenotype, we conducted gain-of-function assays.
IL24 expression was greatly increased in A549 and
SPCA1 cells following the transfection of a pcDNA3.1-
IL24 vector (Fig. 6a + Additional file 1: Figure S1f).
MTT and colony formation assays revealed that overex-
pression of IL24 impaired the proliferation ability of
LAD cells (Fig. 6b, c). Additionally, flow cytometry ana-
lysis confirmed that IL24 upregulation increased G1/G0
arrest and induced cell apoptosis (Fig. 6d, e). Furthermore,
IL24 expression was significantly negative correlated with
LINC00152 expression (Fig. 6f), and the immunohisto-
chemical analysis showed higher IL24 staining in tumors
formed from A549 cells with stable LINC00152 knock-
down (Fig. 6g). These results suggested that the ecotopic
expression of IL24 inhibited cell proliferation and induces
apoptosis in LAD cells.
We also performed rescue assays to validate whether
IL24 was involved in the LINC00152-mediated promo-
tion of LAD cell proliferation. A549 and SPCA1 cells
Table 2 Differentially expressed mRNAs in SPCA1 cells transfected
with si-linc00152 compared with SPCA1 cells as determined by
microarray
mRNAs Regulation Ratio mRNAs Regulation Ratio
Il24 Up 10.63981 GPC6 Down 27.78241
GADD45G Up 8.40941 FGF7 Down 20.73484
HTR6 Up 8.13291 ASTN1 Down 15.33507
NWD2 Up 8.03484 LAMP3 Down 9.11494
GPX7 Up 7.99557 EYA1 Down 8.44694
SHC4 Up 5.52016 RIC3 Down 7.95735
PAGE2 Up 5.12265 GPR85 Down 7.87315
NT5E Up 4.92725 RGSL1 Down 7.26891
LMOD2 Up 4.89948 GPX3 Down 7.02045
DUSP6 Up 3.32944 GPR3 Down 6.23877
CLDN1 Up 3.16901 FLG Down 5.84361
P15 Up 2.85767 A2M Down 6.23877
SPRY4 Up 2.53669 PSG1 Down 3.07936
VDR Up 2.50545 OLR1 Down 2.99577
ACSL5 Up 2.47184 RNF175 Down 2.95313
TNFRSF10B Up 2.10256 GPM7 Down 2.56912
CTSL Up 2.05574 BLCAP Down 2.46682
TTBK2 Up 2.02018 ACSL3 Down 2.25696
PCSK1 Up 2.01142 WDR36 Down 2.12639
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were co-transfected with pcDNA3.1-LINC00152 and
pcDNA3.1-IL24. MTT analysis revealed that IL24 overex-
pression partially reversed the effects of LINC00152
overexpression-mediated promotion of LAD proliferation
(Fig. 7a–c). Western blot analysis showed that IL24
expression levels was decreased in LINC00152 + IL24
cells compared with pcDNA3.1-IL24 transfected cells
(Fig. 7d). Collectively, these data indicated that LINC00152
promoted LAD cell proliferation in part through the
downregulation of IL24.
Discussion
Recently, a number of studies have revealed crucial roles
for lncRNAs in the development and progression of
human cancers. In the case of LAD, several lncRNAs,
such as SPRY4-IT1, LINC01133, AGAP2-AS1, and
LINC00473, have been characterised and their function
have been reported in NSCLC as well as underlying
mechanisms [20–23]. We previously showed that
lncRNA PVT1 is significantly upregulated in LAD tis-
sues and cells, and that it promotes cell proliferation
through epigenetically repressing tumor suppressor
LATS2 expression by interacting with EZH2 [13]. In the
present study, we identified another lncRNA,
LINC00152, which is overexpressed in LAD tissues. In-
creased LINC00152 expression is associated with poor
prognosis and shorter survival time of LAD patients.
Moreover, knockdown of LINC00152 expression inhib-
ited LAD cell proliferation, and induced cell apoptosis
both in vitro and in vivo. These findings suggest that
LINC00152 may exert an oncogenic function and play a
key role in LAD development.
Previous studies demonstrated that LINC00152 is overex-
pressed in multiple cancers, including gastric cancer, HCC,
Fig. 6 Effects of IL24 overexpression in A549 and SPCA1 cell in vitro. a IL24 expression in A549 and SPCA1 cells transfected with pcDNA3.1-IL24 vector.
b, c MTT assays and colony formation assays were used to determine the cell viability. d Cell cycle was analyzed in A549 and SPCA1 cells. e Flow cytometry
was performed to determine the apoptptic rates of cells. f Analysis of LINC00152 and IL24 mRNA levels in 43 paired LAD tissues. g The tumor sections were
under IHC staining using antibodies against IL24. Values are shown as the mean ± s.d in three independent experiments. *P < 0.05, **P < 0.01
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and clear cell renal cell carcinoma. Ji et al. reported that
LINC00152 is upregulated in HCC, and promotes cell pro-
liferation in vitro and tumor growth in vivo through activat-
ing the mTOR pathway by binding to the promoter of the
epithelial cell adhesion molecule gene [24]. Overexpression
of LINC00152 also led to malignant biological behavior in
clear cell renal cell carcinoma through promoting cell pro-
liferation and invasion, and dramatically decreasing
apoptosis [17]. Moreover, increased LINC00152 pro-
moted cell growth and cell cycle progression in gastric
cancer by repressing p15 and p21 transcription
through binding EZH2 [16]. Consistent with these
findings, the present study found that LINC00152
functions as an oncogene by promoting cell prolifera-
tion and anti-apoptosis in LAD cells, suggesting that
it may be a common oncogenic lncRNA in human
cancers.
Increasing evidence has revealed that lncRNAs con-
tribute to tumorigenesis by silencing tumor suppressors
or activating oncogenes through chromatin modification,
genomic imprinting, RNA decay, and sponging miRNAs.
We used RIP and RNA pulldown assays to show that
LINC00152 directly binds EZH2 in LAD cells, suggesting
that LINC00152 regulates underlying targets at the tran-
scriptional level. Further RNA sequencing of LINC00152-
knockdown LAD cells revealed that the tumor suppressor
IL24 is a novel LINC00152 target in LAD cells. Inter-
estingly, knockdown of EZH2 in LAD cells also up-
regulated IL24 expression, while ChIP assays showed
that LINC00152 could recruit EZH2 to the IL24 pro-
moter region and repress its transcription by mediat-
ing H3K27me3. These findings indicate that lncRNA
LINC00152 plays a key role in EZH2-mediated repres-
sion of IL24 in LAD cells.
IL24, also known as melanoma differentiation-associated
gene-7 (MDA-7), is a member of the IL10 cytokine family,
and has been identified as an important immune mediator
as well as a tumor suppressor [25]. Exogenous expression
of IL24 by liposomes or adenoviruses specifically inhibited
cancer cell growth and induced tumor-specific apoptosis in
a broad spectrum of solid tumors, including breast cancer,
neuroblastoma, and HCC [26–28]. IL24 was also shown to
function as a tumor suppressor in hematological malig-
nancies [25, 29] and to cause apoptosis by a secretory
pathway in NSCLC [30], while IL24 overexpression
suppressed migration and invasion in LAD [31]. In the
present study, we also found that overexpression of
IL24 in LAD cells significantly inhibited cell growth
and induced cell apoptosis. Importantly, increased
IL24 expression partially reversed the LINC00152
Fig. 7 IL24 overexpression could partly reverse the oncogenic function of LINC00152. A549 and SPCA1 cells were transfected pcDNA3.1,
pcDNA3.1-LINC00152, pcDNA3.1-IL24, pcDNA3.1-LINC00152 + IL24. a–c MTT assays and colony formation assays were used to determine the
cell viability of transfected LAD cells. The colonies were counted and captured. d The IL24 expression was analyzed in western blotting. Values
are shown as the mean ± s.d in three independent experiments. *P < 0.05, **P < 0.01
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overexpression-induced promotion of growth in LAD
cells, suggesting that the oncogenic role of LINC00152
may depend on IL24 regulation in LAD cells.
Conclusion
We show for the first time that LINC00152 expression
is upregulated in LAD tissues and cells, and that its
overexpression is associated with poor prognosis and
may be a prognostic factor for LAD patients. Knock-
down of LINC00152 exerted tumor suppressive func-
tions through inhibiting cell growth, and inducing cell
apoptosis. Furthermore, LINC00152-mediated onco-
genic effects occur in part through the epigenetic silen-
cing of IL24 expression following binding with EZH2.
We did not determine whether LINC00152 regulates
other genes and mechanisms that underlie regulatory
behavior, so further studies should be carried out to in-
vestigate this. Nevertheless, our findings strengthen the
understanding of LAD pathogenesis, and facilitate the
development of lncRNA-directed diagnostics and ther-
apeutics against this disease.
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Additional file 1: Table S2. Primer sequences. (XLSX 13 kb)
Additional file 2: Figure S1. LINC00152 expression decreased after
LINC00152 silencing. (a) LINC00152 expression in A549 and SPCA1 cells
transfected with three discrete chemically synthesized siRNAs. (b)
LINC00152 expression in H1299 cells transfected with pcDNA3.1-
LINC00152 vector. (c) Western blotting analysis of bcl-xl protein level in
A549 and SPCA1 cells, GAPDH protein was used as an internal control. (d)
EZH2 expression in A549 and SPCA1 cells transfected with si-EZH2. (e)
Western blotting were performed to detect the EZH2 and LSD1 protein
level in A549 and SPCA1 cells. (f) Western blotting analysis of IL24 pro-
tein level in A549 and SPCA1 cells, GAPDH protein was used as an in-
ternal control. Values are shown as the mean ± s.d in three
independent experiments. *P < 0.05, **P < 0.01. (TIF 6891 kb)
Additional file 3: Figure S2. Effects on tumor proliferation after
LINC00152 overexpression in vivo. (a,b) H1299 cells transfected with
empty vector or pcDNA-LINC00152 were injected into the nude mice
(n = 3). Tumors before and after carrying from the nude mice.
(TIF 5996 kb)
Additional file 4: Table S1. Microarray analysis. (XLS 1810 kb)
Additional file 5: Figure S3. LINC00152 could not recruit LSD1 to IL24
promoter. (a) LSD1 expression in A549 and SPCA1 cells transfected with
si-LSD1. (b,c) qRT-PCR and western blotting were performed to detect
the IL24 mRNA and protein level in A549 and SPCA1 cells. (d) ChIP-qRT-
PCR of LSD1 occupancy and H3K4me2 binding in the IL24 promoter in
A549 and SPCA1 cells treated with si-LINC00152(48h) or scrambled siRNA,
IgG was used as a negative control. Values are shown as the mean ± s.d
in three independent experiments. *P < 0.05, **P < 0.01. (TIF 3427 kb)
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